--- title: Diversifying Trials With Health Equity Solutions | Acclinate description: With AI becoming more common across healthcare, find out how advanced health equity solutions are playing a key role in diversifying clinical trials. image: https://blog.acclinate.com/hubfs/Acclinate/Blog%20Images/Health%20Equity%20Solutions%20Leveraging%20Data%20to%20Improve%20Diverse%20Patient%20Recruitment.jpg --- [![Acclinate Logo](https://blog.acclinate.com/hs-fs/hubfs/Acclinate-logo.png?width=2000&height=497&name=Acclinate-logo.png "Acclinate Logo")](https://www.acclinate.com/) - Products - [NOWINCLUDED](https://www.acclinate.com/products/nowincluded-the-community) - [eDICT](https://www.acclinate.com/products/e-dict) - Solutions - [Pharmaceutical Companies](https://www.acclinate.com/solutions/for-pharmaceutical-companies) - [Contract Research Organizations](https://www.acclinate.com/solutions/for-cros) - [Partners](https://www.acclinate.com/solutions/community-partners) - Company - [About Us](https://www.acclinate.com/about) - [Careers](https://www.acclinate.com/careers) - [News](https://news.acclinate.com) - Resources - [Resource Library](https://www.acclinate.com/resources) - [Blog](https://blog.acclinate.com) - [Press Kit](https://www.acclinate.com/press-kit) - [Events](https://www.acclinate.com/events) - [Glossary](https://www.acclinate.com/glossary) - [FAQ](https://www.acclinate.com/faq) - [Talk to Our Team](https://info.acclinate.com/get-in-touch) [![Talk to Our Team](https://no-cache.hubspot.com/cta/default/19943632/2e1c34dc-aaa1-43b8-b5f4-469b0db4e302.png)](https://cta-redirect.hubspot.com/cta/redirect/19943632/2e1c34dc-aaa1-43b8-b5f4-469b0db4e302) [![Acclinate Logo](https://blog.acclinate.com/hs-fs/hubfs/Acclinate_Logo.png?width=500&height=149&name=Acclinate_Logo.png "Acclinate Logo")](https://www.acclinate.com/) - Products - [**NOWINCLUDED**Acclinate’s B2C community platform ](https://www.acclinate.com/products/nowincluded-the-community) - [**e-DICT**Acclinate’s patented AI-powered technology ](https://www.acclinate.com/products/e-dict) - Solutions - [**Pharmaceutical Companies**Community-driven recruitment and real-world insights to support diverse, compliant clinical trials. ](https://www.acclinate.com/solutions/for-pharmaceutical-companies) - [**Contract Research Organization (CRO)**Scalable patient engagement and recruitment solutions that reduce risk and improve enrollment timelines. ](https://www.acclinate.com/solutions/for-cros) - [**Partners**Trusted partnerships that connect research opportunities with the communities they aim to serve. ](https://www.acclinate.com/solutions/community-partners) - Company - [**About us**We help clinical research teams reach diverse communities, build trust, and improve trial participation. ](https://www.acclinate.com/about) - [**Careers**Join a mission-driven team advancing inclusive clinical research and community-powered health innovation. ](https://www.acclinate.com/careers) - Resources - [**Resources Hub** ](https://www.acclinate.com/resources) - [**Glossary** ](https://www.acclinate.com/glossary) - [**Press Kit** ](https://www.acclinate.com/press-kit) - [**Events** ](https://www.acclinate.com/events) - [**Blog** ](https://blog.acclinate.com/) - [**News** ](https://news.acclinate.com/) - [![](https://cdn.prod.website-files.com/695fbca039298e2117988a78/69e7b588548c7ad7bd8ab0bc_9dd915489696393dc63d7785ee2e52c7_Question%20mark%20image.png) **FAQs** ](https://www.acclinate.com/faq) - [ Contact Us ](https://www.acclinate.com/contact-us) Stay up to date Get news directly in your inbox Topic All - [Affective Trust ](https://blog.acclinate.com/tag/affective-trust) - [Announcement ](https://blog.acclinate.com/tag/announcement) - [Clinical Research Software ](https://blog.acclinate.com/tag/clinical-research-software) - [Clinical Trial Recruitment Strategies ](https://blog.acclinate.com/tag/clinical-trial-recruitment-strategies) - [Community ](https://blog.acclinate.com/tag/community) - [Diversity in Clinical Trials ](https://blog.acclinate.com/tag/diversity-in-clinical-trials) - [e-DICT™ ](https://blog.acclinate.com/tag/e-dict) - [FDA Diversity Plan ](https://blog.acclinate.com/tag/fda-diversity-plan) - [FDA Guidance: Diversity in Clinical Trials ](https://blog.acclinate.com/tag/fda-guidance-diversity-in-clinical-trials) - [Health Equity ](https://blog.acclinate.com/tag/health-equity) - [Partnerships ](https://blog.acclinate.com/tag/partnerships) - [Representation in Healthcare ](https://blog.acclinate.com/tag/representation-in-healthcare) [Diversity in Clinical Trials](https://blog.acclinate.com/topic/diversity-in-clinical-trials) # Health Equity Solutions: Leveraging Data to Improve Diverse Patient Recruitment With AI becoming more common across healthcare, find out how advanced health equity solutions are playing a key role in diversifying clinical trials. ![Health Equity Solutions: Leveraging Data to Improve Diverse Patient Recruitment](https://blog.acclinate.com/hubfs/Acclinate/Blog%20Images/Health%20Equity%20Solutions%20Leveraging%20Data%20to%20Improve%20Diverse%20Patient%20Recruitment.jpg) Clinical Trial Diversity: What Does It Really Mean? Clinical trials are critical for evaluating the safety and effectiveness of medical devices and pharmaceutical products. The results of trials guide t... Read More ![ Acclinate](https://blog.acclinate.com/hubfs/69b96486c4b036c19f462c19_acclinate-logo.png) [Acclinate](https://blog.acclinate.com/author/acclinate) Acclinate turns trust and data into better representation. Share this Post: [**](https://www.facebook.com/sharer/sharer.php?u=https://blog.acclinate.com/health-equity-solutions-leveraging-data-to-improve-diverse-patient-recruitment) [**](https://twitter.com/home?status=https://blog.acclinate.com/health-equity-solutions-leveraging-data-to-improve-diverse-patient-recruitment) [** ](https://www.linkedin.com/shareArticle?mini=true&url=https://blog.acclinate.com/health-equity-solutions-leveraging-data-to-improve-diverse-patient-recruitment&title=Diversifying%20Trials%20With%20Health%20Equity%20Solutions%20|%20Acclinate) Stay up to date Get news directly in your inbox **Key Takeaways and Learnings**  - As advanced data analytics and AI take hold in healthcare, sponsors shouldn’t overlook the potential to predict who will engage in clinical trials. - Data analysis can not only uncover who’s a good fit for a trial, but also who faces barriers to participation. - For organizations [addressing ](https://info.acclinate.com/ebook-ultimate-guide-to-advancing-health-equity-in-clinical-trials)[health equity](https://info.acclinate.com/ebook-ultimate-guide-to-advancing-health-equity-in-clinical-trials), solutions ideally should couple deep insights with capabilities to engage with populations on the ground. - Discover [how clinical research software can improve equity](https://blog.acclinate.com/how-can-clinical-research-software-improve-dei-for-clinical-trials) for clinical trials by identifying, engaging, and mobilizing participants.    AI is increasingly taking hold across healthcare. A recent Bain & Co. survey found the number of [health systems with a robust AI strategy](https://www.bain.com/insights/healthcare-it-spending-innovation-integration-ai/) in place has tripled in the last year, while more than 70% are optimistic about generative AI’s potential to improve their organization.   Current and potential use cases for AI abound. Health systems are automating administrative processes, augmenting clinical decision-making, and supporting virtual care. Organizations are also exploring AI’s role in providing health equity solutions that increase access to care and [eliminate bias in treatment decisions](https://www.healthcareitnews.com/news/ai-may-help-improve-equity-pain-treatment-mgb-study-shows)—such as during pain management.  One AI use case that’s often overlooked is the ability to predict clinical trial engagement. Sponsors that can determine the likelihood of an individual to enroll in a trial are positioned to recruit more  representative participants in less time. Furthermore, their trials are more likely to reach an endpoint more aligned with health equity—retaining the right patients to help ensure a trial measures outcomes in historically underserved populations.  Using data to make patient recruitment more diverse is a three-step process. Sponsors need to look for patterns in data with tools such as [e-DICT™](https://blog.acclinate.com/e-DICT-transforms-clinical-trial-recruitment), use the data to inform their recruitment strategies, and pair data-driven recruitment strategies with engaging communities through platforms like [NOWINCLUDED](https://nowincluded.com/). [![Download Now – Before You Recruit: The Ultimate Guide to Advancing Health Equity in Clinical Trials](https://no-cache.hubspot.com/cta/default/19943632/interactive-188916301454.png) ](https://blog.acclinate.com/hs/cta/wi/redirect?encryptedPayload=AVxigLKJpxgES67tdOl9Ajnj%2F9PNNYPA8suS0qVckIE%2FEUB234vvMLZ7aHXZozqdNFy3LYGON8yfxTIfyNehzGO%2B%2BhDm6Mn4Vl%2FAXBl6ShPZV%2FLFdMOpTMDEX5raNr%2FQLABisnRBnkWxX4xPvBylP4%2FyyIXmxBtuw%2FJ%2FsBnF2qi%2B3fuUmT9aRAIFufRbnqEdXZ3L9SeybZQLtrQpFN72rxa7Onyb9qiJU3nEusTSDA7z%2Bw0l%2FlbKqnQn2%2B%2FuPYSh1U1jBQ%3D%3D&webInteractiveContentId=188916301454&portalId=19943632) ## **Step 1** ## **Measuring health equity by looking at patterns in data** Trial sponsors increasingly emphasize [recruitment strategies that increase diversity](https://blog.acclinate.com/clinical-trial-recruitment-strategies-that-increase-diversity). Not only does a [lack of diversity in clinical trials](https://blog.acclinate.com/the-consequences-of-a-lack-of-diversity-in-clinical-trials) lead to skewed data, cost sponsors money, and delay time to market; it also further perpetuates the inequalities that persist in the U.S. healthcare system at large.  Effective strategies for increasing diversity within this context include health equity solutions capable of analyzing vast datasets and identifying patterns related to patient demographics, preferences, and barriers to participation. As the California Health Care Foundation points out, [AI provides a deep dive into data](https://www.chcf.org/blog/harnessing-ais-potential-lift-up-underserved-communities/)—especially unstructured data such as electronic health records—to surface insights that may otherwise go unnoticed. Algorithms can flag individuals based on their medical history or risk factors related to race, gender, or ethnicity—and determine whether they’re good candidates for a treatment option in a trial.   Using [clinical research software driven by AI](https://blog.acclinate.com/how-can-clinical-research-software-improve-dei-for-clinical-trials), sponsors can go a step further and explore factors that may impact an individual’s willingness or ability to participate. Someone may live in a ZIP code that’s far from the trial site and lacks public transit. Or the data may show a community has limited access to broadband Internet, which would make remote monitoring difficult. A platform such as e-DICT™ adds value by aggregating data on engagement with clinical and community content, further indicating the likelihood of an individual’s participation. ## **Step 2** ## **Using data and digital health for equity in recruitment strategies** Once a trial sponsor gains these insights into individuals and populations, it’s important to apply them to recruitment strategies. This will help sponsors dedicate resources appropriately and ensure benchmarks are met, especially those related to enrolling individuals from communities of color.  [AI supports clinical trial recruitment](https://blog.acclinate.com/e-DICT-transforms-clinical-trial-recruitment) in multiple ways. Health equity solutions such as e-DICT™ pair data analysis related to individual and community engagement efforts with qualitative information from sponsor sites. This helps organizations determine which outreach efforts are succeeding and warrant expansion, as well as which content is missing the mark and should be reconsidered.  Additionally, some algorithms can support measuring health equity by prescreening potential participants prior to enrollment. This analysis helps align participants with a study’s inclusion criteria—no small task given the many exclusions increasingly common in trials for highly targeted therapeutics. Algorithms can also flag individuals who meet inclusion criteria but may face barriers to participating in a trial. This can help sponsors anticipate and address challenges in the early stages of trial design—before participants begin to drop out due to predictable circumstances.  ## **Step 3** ## Promoting health equity solutions by pairing analysis with community Increasing diversity in clinical trials requires more than just the latest in digital health. Equity advances when sponsors can truly engage with communities of color. As a recent commentary in *MedCity News* noted, [engagement supported by AI can lead to more equitable access](https://medcitynews.com/2024/10/establishing-better-health-care-outcomes-through-ai/), improve clinical outcomes, and lower overall healthcare costs.  Where e-DICT™ enables targeted, representative clinical research by indicating which communities are more likely to participate, Acclinate’s NOWINCLUDED offers access through digital and in-person engagement facilitated by relationships with organizations that communities of color know and trust. This combination of omnichannel outreach and robust analytics gives sponsors access to communities of color paired with insight into who’s willing to remain engaged because evidence shows they’re the right fit for the trial. ## Leverage advanced digital health equity solutions for your trial Acclinate has been laser-focused on increasing diversity in patient recruitment since e-DICT™ was launched five years ago. Today we continue to explore the role of data and AI in measuring health equity and improving engagement with communities of color. See why more and more clinical research teams are leveraging Acclinate for better health equity data. [Schedule a 1:1 meeting with our team.](https://www.acclinate.com/request-a-demo)  [![Before You Recruit: The Ultimate Guide to Advancing Health Equity in Clinical Trials](https://no-cache.hubspot.com/cta/default/19943632/77a48b61-8ce6-44a3-b69b-3d080ed93db6.png)](https://cta-redirect.hubspot.com/cta/redirect/19943632/77a48b61-8ce6-44a3-b69b-3d080ed93db6) ## Recent Posts [![Clinical Trial Management: The Hidden Risk of Homogeneous Trials in a One-Pivotal-Study World](https://blog.acclinate.com/hubfs/mature-female-patient-at-doctors-appointment-2026-01-08-06-10-47-utc.webp) ](https://blog.acclinate.com/clinical-trial-management-the-hidden-risk-of-homogeneous-trials-in-a-one-pivotal-study-world) [- [Diversity in Clinical Trials](https://blog.acclinate.com/news/tag/diversity-in-clinical-trials) ](https://blog.acclinate.com/clinical-trial-management-the-hidden-risk-of-homogeneous-trials-in-a-one-pivotal-study-world) [ Clinical Trial Management: The Hidden Risk of Homogeneous Trials in a One-Pivotal-Study World ](https://blog.acclinate.com/clinical-trial-management-the-hidden-risk-of-homogeneous-trials-in-a-one-pivotal-study-world) June 25, 2026 3 Min Read Drug development economics are changing. Sponsors are increasingly relying on a single pivotal trial to support approval. Though the goal of this appr... Read More [![Clinical Trial Generalizability: What Regulators Will Scrutinize Next](https://blog.acclinate.com/hubfs/woman-visiting-dermatologist-2026-01-08-22-23-31-utc.webp) ](https://blog.acclinate.com/clinical-trial-generalizability-what-regulators-will-scrutinize-next) [- [Diversity in Clinical Trials](https://blog.acclinate.com/news/tag/diversity-in-clinical-trials) ](https://blog.acclinate.com/clinical-trial-generalizability-what-regulators-will-scrutinize-next) [ Clinical Trial Generalizability: What Regulators Will Scrutinize Next ](https://blog.acclinate.com/clinical-trial-generalizability-what-regulators-will-scrutinize-next) June 25, 2026 3 Min Read For years, generalizability was framed as a methodological concern. Reviewers debated whether results could reasonably extend beyond a trial’s enrolle... Read More [![Site Engagement Index (SEI): Measuring What Actually Builds Trust](https://blog.acclinate.com/hubfs/computer-screen-trading-and-back-with-charts-hom-2026-01-09-09-28-19-utc.webp) ](https://blog.acclinate.com/site-engagement-index-sei-measuring-what-actually-builds-trust) [- [Clinical Research Software](https://blog.acclinate.com/news/tag/clinical-research-software) ](https://blog.acclinate.com/site-engagement-index-sei-measuring-what-actually-builds-trust) [ Site Engagement Index (SEI): Measuring What Actually Builds Trust ](https://blog.acclinate.com/site-engagement-index-sei-measuring-what-actually-builds-trust) June 25, 2026 3 Min Read Clinical research lacks anything but metrics. Enrollment targets, site activation timelines, and digital engagement rates are tracked closely across s... Read More [![](https://blog.acclinate.com/hubfs/Imported_Blog_Media/6567a9f90c0cf111067913e2_Merck%20Pop%20Up2.png) ](https://blog.acclinate.com/acclinate-collaborates-with-merck-to-increase-clinical-trial-diversity) [ Acclinate to support Merck's oncology clinical trials ](https://blog.acclinate.com/acclinate-collaborates-with-merck-to-increase-clinical-trial-diversity) June 24, 2026 1 Min Read Acclinate, an expert in health equity through inclusive research, is collaborating with Merck, known as MSD outside the United States and Canada, to h... Read More [![Why Trial Diversity Is Now a Risk Management Strategy](https://blog.acclinate.com/hubfs/Why-Trial-Diversity-Is-Now-a-Risk-Management-Strategy.jpg) ](https://blog.acclinate.com/why-trial-diversity-is-now-a-risk-management-strategy) [- [Diversity in Clinical Trials](https://blog.acclinate.com/news/tag/diversity-in-clinical-trials) ](https://blog.acclinate.com/why-trial-diversity-is-now-a-risk-management-strategy) [ The New Control Lever: Why Trial Diversity Is Now a Risk Management Strategy ](https://blog.acclinate.com/why-trial-diversity-is-now-a-risk-management-strategy) March 2, 2026 3 Min Read For years, conversations around trial diversity were framed as ethical or reputational concerns. That framing no longer reflects regulatory reality. Read More [![Acclinate’s NOWINCLUDED: Turning Community Insights Into Research Equity](https://blog.acclinate.com/hubfs/AdobeStock_470269560.webp) ](https://blog.acclinate.com/acclinates-nowincluded-turning-community-insights-into-research-equity) [- [Community](https://blog.acclinate.com/news/tag/community) ](https://blog.acclinate.com/acclinates-nowincluded-turning-community-insights-into-research-equity) [ Acclinate’s NOWINCLUDED: Turning Community Insights Into Research Equity ](https://blog.acclinate.com/acclinates-nowincluded-turning-community-insights-into-research-equity) February 16, 2026 3 Min Read Clinical research equity efforts originate with good intentions. But they often hit a roadblock in practice: communities are asked to participate in h... Read More [![How Acclinate’s e-DICT™ Technology Builds Real-Time Community Trust](https://blog.acclinate.com/hubfs/AdobeStock_1631551849.webp) ](https://blog.acclinate.com/how-acclinates-e-dict-technology-builds-real-time-community-trust) [- [Community](https://blog.acclinate.com/news/tag/community) ](https://blog.acclinate.com/how-acclinates-e-dict-technology-builds-real-time-community-trust) [ How Acclinate’s e-DICT™ Technology Builds Real-Time Community Trust ](https://blog.acclinate.com/how-acclinates-e-dict-technology-builds-real-time-community-trust) February 9, 2026 3 Min Read Reaching underrepresented communities in healthcare research has never been simple. Participation decisions are shaped by lived experience, historical... Read More [![Data-Driven Inclusion](https://blog.acclinate.com/hubfs/Acclinate/Blog%20Images/Acclinate-Data-Driven-Inclusion.jpg) ](https://blog.acclinate.com/data-driven-inclusion-predictive-analytics-for-trial-enrollment) [- [Clinical Research Software](https://blog.acclinate.com/news/tag/clinical-research-software) ](https://blog.acclinate.com/data-driven-inclusion-predictive-analytics-for-trial-enrollment) [ Data-Driven Inclusion: Predictive Analytics for Trial Enrollment ](https://blog.acclinate.com/data-driven-inclusion-predictive-analytics-for-trial-enrollment) February 2, 2026 2 Min Read Subpar enrollment remains one of the most common causes of trial delays. But sponsors often miss a key factor: underrepresentation. Lack of diversity ... Read More [![Exploring Diversity in Clinical Research With Acclinate](https://blog.acclinate.com/hubfs/Acclinate/Blog%20Images/Exploring-Diversity-in-Clinical-Research-With-Acclinate.jpg) ](https://blog.acclinate.com/exploring-diversity-in-clinical-research-with-acclinate) [- [Diversity in Clinical Trials](https://blog.acclinate.com/news/tag/diversity-in-clinical-trials) ](https://blog.acclinate.com/exploring-diversity-in-clinical-research-with-acclinate) [ Exploring Diversity in Clinical Research With Acclinate ](https://blog.acclinate.com/exploring-diversity-in-clinical-research-with-acclinate) January 26, 2026 3 Min Read Diversity in clinical research remains a widely discussed goal, yet progress has been uneven. Trials still grapple with subpar representation, limited... Read More [![Clinical Trial Management: The Hidden Risk of Homogeneous Trials in a One-Pivotal-Study World](https://blog.acclinate.com/hubfs/mature-female-patient-at-doctors-appointment-2026-01-08-06-10-47-utc.webp) June 25, 2026 Clinical Trial Management: The Hidden Risk of Homogeneous Trials in a One-Pivotal-Study World Read More ](https://blog.acclinate.com/clinical-trial-management-the-hidden-risk-of-homogeneous-trials-in-a-one-pivotal-study-world) [![Clinical Trial Generalizability: What Regulators Will Scrutinize Next](https://blog.acclinate.com/hubfs/woman-visiting-dermatologist-2026-01-08-22-23-31-utc.webp) June 25, 2026 Clinical Trial Generalizability: What Regulators Will Scrutinize Next Read More ](https://blog.acclinate.com/clinical-trial-generalizability-what-regulators-will-scrutinize-next) [![Site Engagement Index (SEI): Measuring What Actually Builds Trust](https://blog.acclinate.com/hubfs/computer-screen-trading-and-back-with-charts-hom-2026-01-09-09-28-19-utc.webp) June 25, 2026 Site Engagement Index (SEI): Measuring What Actually Builds Trust Read More ](https://blog.acclinate.com/site-engagement-index-sei-measuring-what-actually-builds-trust) ![Woman wearing Acclinate Shirt](https://blog.acclinate.com/hs-fs/hubfs/layer1_image.webp?width=1600&height=1068&name=layer1_image.webp) ![Medical Research Software e-DICT](https://blog.acclinate.com/hs-fs/hubfs/layer2_image.webp?width=885&height=885&name=layer2_image.webp) ![layer2.2_image](https://blog.acclinate.com/hs-fs/hubfs/layer2.2_image.webp?width=1505&height=1197&name=layer2.2_image.webp) ![layer3_image](https://blog.acclinate.com/hs-fs/hubfs/layer3_image.webp?width=1600&height=1067&name=layer3_image.webp) ## Ready to Measure Your True Impact? Partner with Acclinate to turn mission into measurable, data-driven action. [ Get Started ](https://www.acclinate.com/contact-us) [![Acclinate Logo Reversed](https://blog.acclinate.com/hs-fs/hubfs/footer_logo.png?width=1600&height=398&name=footer_logo.png "Acclinate Logo Reversed")](https://www.acclinate.com/) - Products - [NOWINCLUDED](https://www.acclinate.com/products/nowincluded-the-community) - [e-DICT](https://www.acclinate.com/products/e-dict) - Solutions - [Pharmaceutical Companies](https://www.acclinate.com/solutions/for-pharmaceutical-companies) - [CROs](https://www.acclinate.com/solutions/for-cros) - [Community Partners](https://www.acclinate.com/solutions/community-partners) - Resources - [Resources Hub](https://www.acclinate.com/resources) - [Glossary](https://www.acclinate.com/glossary) - [Press Kit](https://www.acclinate.com/press-kit) - [Events](https://www.acclinate.com/events) - [News](https://news.acclinate.com/) - [Blog](https://blog.acclinate.com/) - [FAQs](https://www.acclinate.com/faq) - Company - [About us](https://www.acclinate.com/about) - [Careers](https://www.acclinate.com/careers) - [Contact Us](https://www.acclinate.com/contact-us) - Follow Us - [** Linkedin](https://www.linkedin.com/company/acclinateinc/) - [Privacy Policy](https://www.acclinate.com/privacy) - [Terms of Service](https://www.acclinate.com/terms-of-use-acclinate) ```json { "@context" : "https://schema.org", "@type" : "BlogPosting", "author" : { "@type" : "Person", "name" : "Acclinate", "url" : "https://blog.acclinate.com/author/acclinate" }, "dateModified" : "2026-06-18T19:31:54.466Z", "datePublished" : "2025-04-29T22:04:30.000Z", "headline" : "Diversifying Trials With Health Equity Solutions | Acclinate", "image" : [ "https://blog.acclinate.com/hubfs/Acclinate/Blog%20Images/Health%20Equity%20Solutions%20Leveraging%20Data%20to%20Improve%20Diverse%20Patient%20Recruitment.jpg" ], "mainEntityOfPage" : { "@id" : "https://blog.acclinate.com/health-equity-solutions-leveraging-data-to-improve-diverse-patient-recruitment", "@type" : "WebPage" }, "publisher" : { "@type" : "Organization", "logo" : { "@type" : "ImageObject", "url" : "https://blog.acclinate.com/hubfs/Acclinate-logo.png" }, "name" : "Acclinate" } } ```